miR-944 inhibitors facilitated CIS-induced loss of mitochondrial membrane potential in resistant models, resulting in intrinsic apoptosis via targeting BCL2 interacting protein 3 (BNIP3) [95]. Here, BNIP3 is linked to in situ carcinoma.